血清降钙素原在新型冠状病毒肺炎患者中的应用价值

目的探讨血清降钙素原(Procalcitonin, PCT)在新型冠状病毒肺炎(COVID-19)患者诊疗过程中的应用价值。 方法选取2020年1月至3月期间收治于广州市第八人民医院的399例COVID-19患者作为研究对象，其中轻症组343例，重症组56例，血清PCT累计检测例数798例，选取29例健康人作为对照，检测各组血清PCT并进行比较。 结果重症组血清PCT水平高于对照组和轻症组(P<0.01)；COVID-19伴器官功能衰竭组血清PCT水平高于单纯COVID-19组(P<0.01)；COVID-19合并细菌感染组血清PCT水平高于COVID-19伴器官功能衰竭组与单纯COVID-19组(P<0.01)。 结论当COVID-19患者出现器官功能衰竭或合并细菌感染时，血清PCT水平可出现不同程度的升高，连续监测血清PCT水平，在COVID-19患者的诊疗过程中仍具有一定的应用价值。

Clinical value of procalcitonin in patients with COVID-19

ObjectiveTo investigate the value of procalcitonin (PCT) in the treatment of patients with COVID-19. Methods399 patients with COVID-19 treated in the Eighth People's Hospital of Guangzhou from January to March 2020 were selected as the study subjects, There were 343 mild cases and 56 severe cases.The cumulative number of PCT tests is 798.29 healthy people were selected as the control group. To test the PCT level in each group and compare with each other. ResultsThe level of serum PCT in the severe group was higher than that in the control group or the mild group. The level of PCT in COVID-19 with bacterial infection was higher than that in COVID-19 with organ failure or COVID-19 alone. ConclusionsWhen COVID-19 patients had organ failure or combined with bacterial infection, the serum PCT level could be increased in different degrees. Continuous monitoring of serum PCT levels is still useful in the treatment of patients with COVID-19.